C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 071.3 INR -0.07% Market Closed
Market Cap: 216.7B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note

Operating Margin
Concord Biotech Ltd

37.3%
Current
36%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
37.3%
=
Operating Profit
4B
/
Revenue
10.9B

Operating Margin Across Competitors

Country IN
Market Cap 216.7B INR
Operating Margin
37%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 749.7B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 372B USD
Operating Margin
28%
Country US
Market Cap 257.3B USD
Operating Margin
34%
Country CH
Market Cap 200.6B CHF
Operating Margin
32%
Country UK
Market Cap 162.5B GBP
Operating Margin
21%
Country CH
Market Cap 179.9B CHF
Operating Margin
31%
Country US
Market Cap 146B USD
Operating Margin
22%
No Stocks Found

Concord Biotech Ltd
Glance View

Market Cap
216.7B INR
Industry
Pharmaceuticals

Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.

CONCORDBIO Intrinsic Value
1 110.45 INR
Overvaluation 46%
Intrinsic Value
Price
C

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
37.3%
=
Operating Profit
4B
/
Revenue
10.9B
What is the Operating Margin of Concord Biotech Ltd?

Based on Concord Biotech Ltd's most recent financial statements, the company has Operating Margin of 37.3%.